AR047061A1 - Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida - Google Patents

Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida

Info

Publication number
AR047061A1
AR047061A1 ARP040104756A ARP040104756A AR047061A1 AR 047061 A1 AR047061 A1 AR 047061A1 AR P040104756 A ARP040104756 A AR P040104756A AR P040104756 A ARP040104756 A AR P040104756A AR 047061 A1 AR047061 A1 AR 047061A1
Authority
AR
Argentina
Prior art keywords
renzapride
hydrached
azabiciclo
benzamida
metoxi
Prior art date
Application number
ARP040104756A
Other languages
English (en)
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Publication of AR047061A1 publication Critical patent/AR047061A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente provee procesos para preparar clorhidrato de renzapride Forma II, clorhidrato hidratado de renzapride Forma II cristalino a un nivel de 75% o más y usos de los mismos. Reivindicacion 1: Un proceso para la produccion de clorhidrato hidratado de renzapride Foerma II que comprende incubar renzapride en una solucion de agua y un solvente miscible en agua, seguido por el agregado de ácido clorhídrico concentrado a la solucion de renzapride y el aislamiento de clorhidrato hidratado de renzapride Forma II mediante filtrado.
ARP040104756A 2003-12-18 2004-12-17 Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida AR047061A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0329319.8A GB0329319D0 (en) 2003-12-18 2003-12-18 Synthesis

Publications (1)

Publication Number Publication Date
AR047061A1 true AR047061A1 (es) 2006-01-04

Family

ID=30471293

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104756A AR047061A1 (es) 2003-12-18 2004-12-17 Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida

Country Status (17)

Country Link
US (1) US20050209271A1 (es)
EP (1) EP1699789A2 (es)
JP (1) JP2007514726A (es)
KR (1) KR20060123436A (es)
CN (1) CN1894248A (es)
AR (1) AR047061A1 (es)
AU (1) AU2004299338A1 (es)
BR (1) BRPI0417733A (es)
CA (1) CA2548781A1 (es)
GB (1) GB0329319D0 (es)
IL (1) IL176130A0 (es)
MX (1) MXPA06006838A (es)
NO (1) NO20063299L (es)
RU (1) RU2337102C2 (es)
TW (1) TW200528108A (es)
WO (1) WO2005058896A2 (es)
ZA (1) ZA200604876B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321091D0 (en) * 2003-09-09 2003-10-08 Alizyme Therapeutics Ltd Synthesis
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
US11267786B2 (en) 2018-06-01 2022-03-08 Merck Sharp & Dohme Corp. [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223873A (en) * 1982-04-14 1987-07-07 Francis D. King Pharmaceutically active compounds
GB8607163D0 (en) * 1986-03-22 1986-04-30 Beecham Group Plc Chemical compound
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
WO2005058896A3 (en) 2005-08-11
CA2548781A1 (en) 2005-06-30
AU2004299338A1 (en) 2005-06-30
US20050209271A1 (en) 2005-09-22
RU2006120196A (ru) 2008-01-27
KR20060123436A (ko) 2006-12-01
TW200528108A (en) 2005-09-01
JP2007514726A (ja) 2007-06-07
EP1699789A2 (en) 2006-09-13
CN1894248A (zh) 2007-01-10
NO20063299L (no) 2006-07-17
GB0329319D0 (en) 2004-01-21
MXPA06006838A (es) 2006-09-04
WO2005058896A2 (en) 2005-06-30
IL176130A0 (en) 2006-10-05
RU2337102C2 (ru) 2008-10-27
ZA200604876B (en) 2007-11-28
BRPI0417733A (pt) 2007-04-03

Similar Documents

Publication Publication Date Title
CY1121583T1 (el) Πολυμορφικες και ψευδοπολυμορφικες μορφες της φαρμακευτικης ενωσης nxl104
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
UA100367C2 (uk) Спосіб одержання мемантину і його гідрохлориду
CR7080A (es) Sales tartrato de 5,8,14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
BRPI0510231A (pt) composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo
AR068527A2 (es) Un procedimiento para preparar monohidrato de bromuro de tiotropio cristalino
BRPI0402382A (pt) Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais
ECSP045221A (es) Sales de valsartan
AR052301A1 (es) Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas
CL2011000166A1 (es) Metodo para preparar tetrahidrobiopterina hidrolizando diacetilbiopterina a biopterina en presencia de una base en una mezcla bifasica de agua y solvente organico no miscible en agua e hidrogenando biopterina a tetrahidrobiopterina en presencia de un catalizador, ambas etapas a un ph de al menos 10 (divisional de la solicitud de patente de invencion no. 7-2009).
DK1761478T3 (da) En isoleret Atomoxetin urenhed, fremgangsmåde til fremstilling af Atomoxetin urenheder og deres anvendelse som referencestandarder
AR057291A1 (es) Proceso para la preparacion de acidos bisfosfonicos geminales y las sales y/o hidratos farmaceuticamente aceptables de los mismos, una composicion farmaceutica que los contiene y el uso de esta en el tratamiento de la osteoporosis
PE20040767A1 (es) Derivado hemisulfato de azido citosina cristalino anhidro
HK1073102A1 (en) Sulphonic acid salts of mandelic acid derivatives
UY27786A1 (es) Derivados de isoquinolina.
UY27842A1 (es) Fluorobenzamidas
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
AR047061A1 (es) Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida
ECSP045136A (es) Polimorfo de clorhidrato de venlafaxina novedoso y metodos para la preparacion del mismo
NO20073440L (no) Prosess for fremstilling av candesartan
IL169496A0 (en) Imino acid derivatives for use as inhibitors of matrix metalloproteinases
AR043037A1 (es) Benzo [1,2,5] tiadiazoles y su uso farmaceutico
HUP0204111A2 (hu) Új eljárás alfa-(2,4-diszulfo-fenil)-N-terc-butil-nitron és gyógyszerészetileg elfogadható sói előállítására
AR045681A1 (es) Proceso para la sintesis de intermediarios de inhibidores de betalactamasa
AP1511A (en) Process for the isolation of crystalline imipenem.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal